EpimAb Biotherapeutics, Innovent Biologics deal

EpimAb granted Innovent rights to Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform to develop bispecific antibodies against multiple targets. Innovent has rights in China to any programs developed using the platform and rights to out-license those programs outside of China. ...